PMID- 29654297
OWN - NLM
STAT- MEDLINE
DCOM- 20190819
LR  - 20230411
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
VI  - 14
IP  - 6
DP  - 2018 Jun
TI  - CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease.
PG  - 361-377
LID - 10.1038/s41581-018-0001-y [doi]
AB  - The increasing global prevalence of type 2 diabetes mellitus (T2DM) and chronic 
      kidney disease (CKD) has prompted research efforts to tackle the growing epidemic 
      of diabetic kidney disease (DKD; also known as diabetic nephropathy). The limited 
      success of much of this research might in part be due to the fact that not all 
      patients diagnosed with DKD have renal dysfunction as a consequence of their 
      diabetes mellitus. Patients who present with CKD and diabetes mellitus (type 1 or 
      type 2) can have true DKD (wherein CKD is a direct consequence of their diabetes 
      status), nondiabetic kidney disease (NDKD) coincident with diabetes mellitus, or 
      a combination of both DKD and NDKD. Preclinical studies using models that more 
      accurately mimic these three entities might improve the ability of animal models 
      to predict clinical trial outcomes. Moreover, improved insights into the 
      pathomechanisms that are shared by these entities - including sodium-glucose 
      cotransporter 2 (SGLT2) and renin-angiotensin system-driven glomerular 
      hyperfiltration and tubular hyper-reabsorption - as well as those that are unique 
      to individual entities might lead to the identification of new treatment targets. 
      Acknowledging that the clinical entity of CKD plus diabetes mellitus encompasses 
      NDKD as well as DKD could help solve some of the urgent unmet medical needs of 
      patients affected by these conditions.
FAU - Anders, Hans-Joachim
AU  - Anders HJ
AUID- ORCID: 0000-0003-2434-2956
AD  - Division of Nephrology, Medizinische Klinik and Poliklinik IV, Klinikum der LMU 
      Munchen - Innenstadt, Munchen, Germany. hjanders@med.uni-muenchen.de.
FAU - Huber, Tobias B
AU  - Huber TB
AD  - III. Department of Medicine, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Isermann, Berend
AU  - Isermann B
AD  - Institute of Clinical Chemistry and Pathobiochemistry, Otto von Guericke 
      University Magdeburg, Magdeburg, Germany.
FAU - Schiffer, Mario
AU  - Schiffer M
AD  - Department of Nephrology, Hannover Medical School, Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
MH  - Animals
MH  - Biopsy
MH  - Cardiovascular Diseases/diagnosis/*physiopathology/prevention & control
MH  - Diabetes Mellitus/*physiopathology
MH  - Diabetic Nephropathies/diagnosis/*physiopathology/prevention & control
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Primary Prevention
MH  - Renin-Angiotensin System
MH  - Sodium-Glucose Transporter 2
EDAT- 2018/04/15 06:00
MHDA- 2019/08/20 06:00
CRDT- 2018/04/15 06:00
PHST- 2018/04/15 06:00 [pubmed]
PHST- 2019/08/20 06:00 [medline]
PHST- 2018/04/15 06:00 [entrez]
AID - 10.1038/s41581-018-0001-y [pii]
AID - 10.1038/s41581-018-0001-y [doi]
PST - ppublish
SO  - Nat Rev Nephrol. 2018 Jun;14(6):361-377. doi: 10.1038/s41581-018-0001-y.